Napthalimidobenzamide DB-51630: A novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity

Kenji Suzuki, Hideko Nagasawa, Yoshihiro Uto, Yoshikazu Sugimoto, Kazuharu Noguchi, Motoji Wakida, Konstanty Wierzba, Tadafumi Terada, Tetsuji Asao, Yuji Yamada, Kenji Kitazato, Hitoshi Hori

研究成果: Article

27 引用 (Scopus)

抄録

Control of gene expression by small molecule compounds is a novel therapeutic strategy for cancer and usually it requires the presence of specific molecular recognition. The development of the compounds preferentially binding to the specific DNA sequence is one of the potential but very difficult approaches in this strategy. We designed and synthesized novel napthalimidobenzamide derivatives and analyzed their binding preferences to oligonucleotides by EtBr-displacement assay with DNA sequences, being essential fragments of the genes. To test whether these compounds modify the expression of specific genes, we analyzed the effect on the gene expression in AZ521 cells by differential display analysis using the compounds showing different characteristics in the recognition of specific DNA sequence. Among them, DB-51630, which showed approximately 350 times higher preferential binding to GC-repeats than to the AT and AA-repeating oligomers, caused the induction of a specific mRNA. The genetic sequence was identified to be the p300 gene by sequencing of the cloned cDNA. The p300 is a transcriptional co-activator protein that acts with other nuclear proteins in various cell differentiation and signal transduction pathways. This protein has intrinsic histone acetyltransferase activity and may act on chromatin directly to facilitate transcription. The increase of the amount of p300 mRNA increased after DB-51630 treatment by real time RT-PCR and Northern blot analysis. DB-51630 inhibited cell growth in various cancer cell lines at nanomolar range of concentrations, whereas p300 mRNA induction was observed at sub-nanomolar concentrations and the maximal induction occurred 8 h after DB-51630 treatment. In contrast, anti-cancer drugs such as doxorubicin, vincristine, cisplatin, etoposide, and actinomycin D did not increase p300 transcription. DB-51630 revealed potent anti-cancer activity against human solid tumor xenografts. Thus, we demonstrated the anti-cancer activity of DB-51630, which interacts with a specific DNA sequence, thereby inducing p300 gene expression and exhibited significant anti-cancer activity in human tumor xenografts. Furthermore, such compounds that bind to specific DNA sequences may not only control the expression of specific genes but also exert other mechanisms in the anti-cancer effect than those of classical DNA binding drugs.

元の言語English
ページ(範囲)4014-4021
ページ数8
ジャーナルBioorganic and Medicinal Chemistry
13
発行部数12
DOI
出版物ステータスPublished - 2005 6 2
外部発表Yes

Fingerprint

DNA sequences
Gene expression
Gene Expression
Genes
DNA
Transcription
Neoplasms
Heterografts
Messenger RNA
Tumors
Histone Acetyltransferases
Molecular recognition
Signal transduction
Cell growth
Dactinomycin
Human Activities
Vincristine
Etoposide
Nuclear Proteins
Oligomers

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

これを引用

Napthalimidobenzamide DB-51630 : A novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity. / Suzuki, Kenji; Nagasawa, Hideko; Uto, Yoshihiro; Sugimoto, Yoshikazu; Noguchi, Kazuharu; Wakida, Motoji; Wierzba, Konstanty; Terada, Tadafumi; Asao, Tetsuji; Yamada, Yuji; Kitazato, Kenji; Hori, Hitoshi.

:: Bioorganic and Medicinal Chemistry, 巻 13, 番号 12, 02.06.2005, p. 4014-4021.

研究成果: Article

Suzuki, K, Nagasawa, H, Uto, Y, Sugimoto, Y, Noguchi, K, Wakida, M, Wierzba, K, Terada, T, Asao, T, Yamada, Y, Kitazato, K & Hori, H 2005, 'Napthalimidobenzamide DB-51630: A novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity', Bioorganic and Medicinal Chemistry, 巻. 13, 番号 12, pp. 4014-4021. https://doi.org/10.1016/j.bmc.2005.03.053
Suzuki, Kenji ; Nagasawa, Hideko ; Uto, Yoshihiro ; Sugimoto, Yoshikazu ; Noguchi, Kazuharu ; Wakida, Motoji ; Wierzba, Konstanty ; Terada, Tadafumi ; Asao, Tetsuji ; Yamada, Yuji ; Kitazato, Kenji ; Hori, Hitoshi. / Napthalimidobenzamide DB-51630 : A novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity. :: Bioorganic and Medicinal Chemistry. 2005 ; 巻 13, 番号 12. pp. 4014-4021.
@article{eeb9360f655949bebf4f125ed1cfaa66,
title = "Napthalimidobenzamide DB-51630: A novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity",
abstract = "Control of gene expression by small molecule compounds is a novel therapeutic strategy for cancer and usually it requires the presence of specific molecular recognition. The development of the compounds preferentially binding to the specific DNA sequence is one of the potential but very difficult approaches in this strategy. We designed and synthesized novel napthalimidobenzamide derivatives and analyzed their binding preferences to oligonucleotides by EtBr-displacement assay with DNA sequences, being essential fragments of the genes. To test whether these compounds modify the expression of specific genes, we analyzed the effect on the gene expression in AZ521 cells by differential display analysis using the compounds showing different characteristics in the recognition of specific DNA sequence. Among them, DB-51630, which showed approximately 350 times higher preferential binding to GC-repeats than to the AT and AA-repeating oligomers, caused the induction of a specific mRNA. The genetic sequence was identified to be the p300 gene by sequencing of the cloned cDNA. The p300 is a transcriptional co-activator protein that acts with other nuclear proteins in various cell differentiation and signal transduction pathways. This protein has intrinsic histone acetyltransferase activity and may act on chromatin directly to facilitate transcription. The increase of the amount of p300 mRNA increased after DB-51630 treatment by real time RT-PCR and Northern blot analysis. DB-51630 inhibited cell growth in various cancer cell lines at nanomolar range of concentrations, whereas p300 mRNA induction was observed at sub-nanomolar concentrations and the maximal induction occurred 8 h after DB-51630 treatment. In contrast, anti-cancer drugs such as doxorubicin, vincristine, cisplatin, etoposide, and actinomycin D did not increase p300 transcription. DB-51630 revealed potent anti-cancer activity against human solid tumor xenografts. Thus, we demonstrated the anti-cancer activity of DB-51630, which interacts with a specific DNA sequence, thereby inducing p300 gene expression and exhibited significant anti-cancer activity in human tumor xenografts. Furthermore, such compounds that bind to specific DNA sequences may not only control the expression of specific genes but also exert other mechanisms in the anti-cancer effect than those of classical DNA binding drugs.",
keywords = "DB-51630, DNA binding agents, p300",
author = "Kenji Suzuki and Hideko Nagasawa and Yoshihiro Uto and Yoshikazu Sugimoto and Kazuharu Noguchi and Motoji Wakida and Konstanty Wierzba and Tadafumi Terada and Tetsuji Asao and Yuji Yamada and Kenji Kitazato and Hitoshi Hori",
year = "2005",
month = "6",
day = "2",
doi = "10.1016/j.bmc.2005.03.053",
language = "English",
volume = "13",
pages = "4014--4021",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Napthalimidobenzamide DB-51630

T2 - A novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity

AU - Suzuki, Kenji

AU - Nagasawa, Hideko

AU - Uto, Yoshihiro

AU - Sugimoto, Yoshikazu

AU - Noguchi, Kazuharu

AU - Wakida, Motoji

AU - Wierzba, Konstanty

AU - Terada, Tadafumi

AU - Asao, Tetsuji

AU - Yamada, Yuji

AU - Kitazato, Kenji

AU - Hori, Hitoshi

PY - 2005/6/2

Y1 - 2005/6/2

N2 - Control of gene expression by small molecule compounds is a novel therapeutic strategy for cancer and usually it requires the presence of specific molecular recognition. The development of the compounds preferentially binding to the specific DNA sequence is one of the potential but very difficult approaches in this strategy. We designed and synthesized novel napthalimidobenzamide derivatives and analyzed their binding preferences to oligonucleotides by EtBr-displacement assay with DNA sequences, being essential fragments of the genes. To test whether these compounds modify the expression of specific genes, we analyzed the effect on the gene expression in AZ521 cells by differential display analysis using the compounds showing different characteristics in the recognition of specific DNA sequence. Among them, DB-51630, which showed approximately 350 times higher preferential binding to GC-repeats than to the AT and AA-repeating oligomers, caused the induction of a specific mRNA. The genetic sequence was identified to be the p300 gene by sequencing of the cloned cDNA. The p300 is a transcriptional co-activator protein that acts with other nuclear proteins in various cell differentiation and signal transduction pathways. This protein has intrinsic histone acetyltransferase activity and may act on chromatin directly to facilitate transcription. The increase of the amount of p300 mRNA increased after DB-51630 treatment by real time RT-PCR and Northern blot analysis. DB-51630 inhibited cell growth in various cancer cell lines at nanomolar range of concentrations, whereas p300 mRNA induction was observed at sub-nanomolar concentrations and the maximal induction occurred 8 h after DB-51630 treatment. In contrast, anti-cancer drugs such as doxorubicin, vincristine, cisplatin, etoposide, and actinomycin D did not increase p300 transcription. DB-51630 revealed potent anti-cancer activity against human solid tumor xenografts. Thus, we demonstrated the anti-cancer activity of DB-51630, which interacts with a specific DNA sequence, thereby inducing p300 gene expression and exhibited significant anti-cancer activity in human tumor xenografts. Furthermore, such compounds that bind to specific DNA sequences may not only control the expression of specific genes but also exert other mechanisms in the anti-cancer effect than those of classical DNA binding drugs.

AB - Control of gene expression by small molecule compounds is a novel therapeutic strategy for cancer and usually it requires the presence of specific molecular recognition. The development of the compounds preferentially binding to the specific DNA sequence is one of the potential but very difficult approaches in this strategy. We designed and synthesized novel napthalimidobenzamide derivatives and analyzed their binding preferences to oligonucleotides by EtBr-displacement assay with DNA sequences, being essential fragments of the genes. To test whether these compounds modify the expression of specific genes, we analyzed the effect on the gene expression in AZ521 cells by differential display analysis using the compounds showing different characteristics in the recognition of specific DNA sequence. Among them, DB-51630, which showed approximately 350 times higher preferential binding to GC-repeats than to the AT and AA-repeating oligomers, caused the induction of a specific mRNA. The genetic sequence was identified to be the p300 gene by sequencing of the cloned cDNA. The p300 is a transcriptional co-activator protein that acts with other nuclear proteins in various cell differentiation and signal transduction pathways. This protein has intrinsic histone acetyltransferase activity and may act on chromatin directly to facilitate transcription. The increase of the amount of p300 mRNA increased after DB-51630 treatment by real time RT-PCR and Northern blot analysis. DB-51630 inhibited cell growth in various cancer cell lines at nanomolar range of concentrations, whereas p300 mRNA induction was observed at sub-nanomolar concentrations and the maximal induction occurred 8 h after DB-51630 treatment. In contrast, anti-cancer drugs such as doxorubicin, vincristine, cisplatin, etoposide, and actinomycin D did not increase p300 transcription. DB-51630 revealed potent anti-cancer activity against human solid tumor xenografts. Thus, we demonstrated the anti-cancer activity of DB-51630, which interacts with a specific DNA sequence, thereby inducing p300 gene expression and exhibited significant anti-cancer activity in human tumor xenografts. Furthermore, such compounds that bind to specific DNA sequences may not only control the expression of specific genes but also exert other mechanisms in the anti-cancer effect than those of classical DNA binding drugs.

KW - DB-51630

KW - DNA binding agents

KW - p300

UR - http://www.scopus.com/inward/record.url?scp=21144447742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144447742&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2005.03.053

DO - 10.1016/j.bmc.2005.03.053

M3 - Article

C2 - 15911314

AN - SCOPUS:21144447742

VL - 13

SP - 4014

EP - 4021

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 12

ER -